Jinling Pharmaceutical Company Limited
000919.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.15B
Close$
$2.36
63.1% downside
Current Fair Value
63.1% downsideOvervalued by 63.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.15 Billion |
|---|---|
| Enterprise Value | $3.16 Billion |
| Dividend Yield | $0.10 (1.50%) |
| Earnings per Share | $0.09 |
| Beta | 0.27 |
| Outstanding Shares | 621,924,528 |
Return
| Return on Equity | 1.49% |
|---|---|
| Return on Assets | 0.93% |
| Return on Invested Capital | 1.30% |
Valuation & Multiples
| P/E Ratio | 74.11 |
|---|---|
| PEG | -632.13 |
| Price to Sales | 1.28 |
| Price to Book Ratio | 0.91 |
| Enterprise Value to Revenue | 0.99 |
| Enterprise Value to EBIT | 47.96 |
| Enterprise Value to Net Income | 56 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Jinling Pharmaceutical Company Limited
5,716 employees
CEO: Hai Chen Jinling Pharmaceutical Company Limited is a Chinese enterprise specializing in the manufacture and distribution of a diverse range of pharmaceutical products. Its key offerings include the Mailuoning injection, prescribed for the managem...